Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SORBITRATE vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Prophylaxis of angina pectoris (to reduce frequency and severity of anginal attacks),Chronic management of angina pectoris (as part of long-term therapy),Off-label: Congestive heart failure (adjunctive therapy to reduce preload and afterload),Off-label: Esophageal spasm (symptomatic relief)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Terminal elimination half-life: 5–6 hours. Clinical context: supports dosing every 6–8 hours; requires nitrate-free interval to prevent tolerance.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Isosorbide dinitrate undergoes extensive first-pass metabolism in the liver via glutathione-dependent organic nitrate reductase (likely mediated by mitochondrial aldehyde dehydrogenase, ALDH2) to active metabolites isosorbide-2-mononitrate and isosorbide-5-mononitrate, with the latter being the major active metabolite. These metabolites are further glucuronidated and excreted renally.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal: ~20% unchanged; remainder as metabolites (isosorbide-2-mononitrate, isosorbide-5-mononitrate). Biliary/fecal: negligible.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
~28% bound to albumin.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
Vd: 1.5–3.5 L/kg. Clinical meaning: extensive tissue distribution, high uptake in vascular smooth muscle.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: ~40–60% (bypasses first-pass metabolism). Oral: ~10–20% (extensive first-pass hepatic metabolism).
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dose adjustment required. GFR <10 m L/min: limited data, consider reduced dose.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% or extend dosing interval.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Not recommended for children <18 years due to lack of safety data.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Start at lower end of dosing range (e.g., sublingual 2.5 mg, oral 10 mg twice daily) due to increased sensitivity and risk of hypotension.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
No FDA boxed warning.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension: May cause severe hypotension, especially upon standing (orthostatic hypotension). Correct hypovolemia before use.,Tolerance: Continuous use may lead to development of tolerance; a daily nitrate-free interval (10-12 hours) is recommended to maintain efficacy.,Headache: Common, often dose-limiting; may be severe initially but decreases with continued use.,Worsening angina: Abrupt discontinuation may precipitate angina; taper gradually.,Hypertrophic cardiomyopathy: Use with caution in patients with hypertrophic obstructive cardiomyopathy as vasodilation may worsen outflow obstruction.,Increased intracranial pressure: Use with caution in patients with increased intracranial pressure (e.g., head trauma, cerebral hemorrhage).
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to isosorbide dinitrate or any component of the formulation,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe hypotension (systolic BP < 90 mm Hg),Cardiogenic shock (unless used to maintain coronary perfusion pressure with inotropic support),Obstructive cardiomyopathy (relative contraindication),Increased intracranial pressure (relative contraindication)
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
No significant food interactions, but high-fat meals may delay absorption. Avoid excessive alcohol, which can cause additive vasodilation and hypotension.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a potential risk of fetal hypoxia, especially during the second and third trimesters. Use only if clearly needed.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
It is not known if isosorbide dinitrate is excreted in human milk. The M/P ratio is unknown. Because many drugs are excreted in milk, caution should be exercised when administered to a nursing woman.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No specific dose adjustments are recommended, but due to increased plasma volume and altered hemodynamics in pregnancy, lower starting doses may be considered, titrating to clinical response. Monitor for hypotension.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Sorbitrate (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis, not acute attacks. Sublingual form has faster onset; oral sustained-release provides longer duration. Tolerance develops rapidly with continuous dosing; use a 10-12 hour nitrate-free interval daily. Monitor for hypotension, especially with concurrent PDE-5 inhibitors (e.g., sildenafil) – absolute contraindication due to severe hypotension risk. Headache is common, often transient; advise analgesia. Avoid abrupt discontinuation.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Take exactly as prescribed, do not stop abruptly.,For sublingual tablets: place under tongue and let dissolve; do not swallow.,Avoid alcohol as it can worsen dizziness and hypotension.,Prolonged use may lead to tolerance; a daily nitrate-free period is important.,Store tablets in original glass container away from heat and moisture.,Do not use within 24 hours of erectile dysfunction drugs like Viagra, Cialis, or Levitra.,Common side effects: headache, flushing, dizziness; contact doctor if severe or persistent.,If chest pain persists after one sublingual dose, call 911 immediately.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SORBITRATE vs MONOKET, answered by our medical review team.
SORBITRATE is a Nitrate vasodilator that works by Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SORBITRATE and MONOKET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SORBITRATE is: Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SORBITRATE and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SORBITRATE is classified as Category C. Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a poten. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.